Arbutus Biopharma CorporationABUSNASDAQ

|||

Overview Charts News Fundamentals Key Metrics TTM Financials Earnings Growth Rating Analysts Institutional Peers Historical

Analyst Sentiment

Analysts lean bullish — 80% recommend buying.

Consensus Rating

Buy

10 analysts·Moderate coverage

80%

Rating Distribution

Strong Buy

00%

Buy

880%

Hold

220%

Sell

00%

Strong Sell

00%

Analyst ratings reflect Wall Street opinion, not guarantees. Historical accuracy varies by firm and sector.

Price Target Expectations

Analysts see significant upside — consensus target 132% higher.

Bear Case

$8.50

+132%

Consensus

$8.50

+132%

Bull Case

$8.50

+132%

Price Range10 analysts

Low

Consensus

High

$8.50

Current Target

Current Price

$3.67

Upside to Target

$4.83

Price targets are 12-month forecasts. Actual results depend on earnings, market conditions, and sector trends.

Earnings & Revenue Estimates

2026E$-0.16(1 analysts)

Actual

Estimate

Range (Low–High)

Stock Alarm Pro

Forward Growth Estimates (YoY)

FY2027

Rev+783.20%

EPS—

FY2028

Rev+533.46%

EPS—

FY2029

Rev+210.17%

EPS—

Earnings Surprises

Beat rate:42%(5/12 quarters)

Avg surprise:+15.2%

Beat

Miss

Inline

Estimate

Based on reported EPS vs consensus estimate.

Recent Analyst Actions

Mar 17, 2022H.C. Wainwright

Arbutus Biopharma (ABUS) Stock: $8.50 Price Target And Buy Rating

Target:$8.50

+181.5%from $3.02

Explore More

S&P 500 Screener

Filter and sort all 500 stocks

Market Movers

Today's biggest gainers and losers

Market Heatmap

Visual sector performance